Year: 2025

  • Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016

    Proposed fundraising to finance the pivotal Phase III trial for the Company’s lead product, Lupuzor™ Friday, February 5, 2016 – 10:46 ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce a proposed conditional fund raise of not less than £7.5 million. This includes a proposed conditional…

  • Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a summary of the Investigators Meeting which was held in Paris on 11th/12th  December. The key objective of the event was to bring together key specialists in the field of Lupus who will be actively involved as…

  • Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. The Company is pleased to confirm that…

  • Lupuzor™ Phase III Pivotal Trial Update

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide an update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. The pivotal Phase III trial is progressing in…

  • Board Change

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that Ajay Agrawal has stepped down as Non-Executive Director with immediate effect. Tim McCarthy, Non-Executive Chairman said: “We would like to thank Ajay for his contribution whilst at ImmuPharma.  “In the short period of time as Chairman, I have become…

  • Tim McCarthy Appointed as Non-executive Chairman

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect. Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a…

  • Interim Results Announcement for the six months ended 30 June 2015

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2015 (the “Period”). Although we are pleased to report our interim results, we are saddened by the passing of our Chairman, Richard Warr, in late July.  …

  • Richard Warr

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is truly saddened to announce that Richard Warr, Chairman, passed away late last week. Dimitri Dimitrou, Chief Executive Director said: “No words can truly convey the deep sadness we feel at Richard’s untimely passing away. Richard will be remembered and missed…

  • ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that registration with the U.S. National Institutes of Health – ClincialTrials.gov website has now gone ‘live’ confirming Lupuzor’s™ pivotal Phase III trial protocol and the current clinical commencement and completion of the study. Further details can be…

  • Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

    ImmuPharma has also signed a Term Sheet with a US investor for a proposed private placement to fund the clinical trial. The initial instalment of funding consists of a convertible loan of US$2,000,000 plus additional capital of up to US$12,000,000, at the Company’s discretion, subject to certain criteria, over a two year period. Further disclosure…